Free Trial
NASDAQ:SBTX

Silverback Therapeutics (SBTX) Stock Price, News & Analysis

Silverback Therapeutics logo
$14.52 +0.30 (+2.11%)
As of 05/22/2025

About Silverback Therapeutics Stock (NASDAQ:SBTX)

Key Stats

Today's Range
$14.03
$14.57
50-Day Range
$11.53
$15.00
52-Week Range
$2.80
$8.97
Volume
875,800 shs
Average Volume
337,931 shs
Market Capitalization
$523.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SBTX Stock News Headlines

ARS Pharmaceuticals Inc (SPRY)
SPRY ARS Pharmaceuticals, Inc.
Trump Makes Major Crypto Announcement
You Won’t Get a Second Chance at This Entry The crypto comeback isn't coming—it's already here. And one particular coin is sitting right at the center of this shift.
See More Headlines

SBTX Stock Analysis - Frequently Asked Questions

Silverback Therapeutics' stock was trading at $10.55 on January 1st, 2025. Since then, SBTX stock has increased by 37.6% and is now trading at $14.52.
View the best growth stocks for 2025 here
.

Silverback Therapeutics, Inc. (NASDAQ:SBTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65).

Silverback Therapeutics (SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel acted as the underwriters for the IPO and H.C. Wainwright was co-manager.

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silverback Therapeutics investors own include Athenex (ATNX), AbbVie (ABBV), Applied Materials (AMAT), JPMorgan Chase & Co. (JPM), Luminar Technologies (LAZR), Lineage Cell Therapeutics (LCTX) and Aviat Networks (AVNW).

Company Calendar

Last Earnings
11/10/2021
Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBTX
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$7.41 per share
Price / Book
1.96

Miscellaneous

Free Float
23,654,000
Market Cap
$523.56 million
Optionable
Not Optionable
Beta
0.60
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:SBTX) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners